Ed Arce
Stock Analyst at HC Wainwright & Co.
(3.83)
# 663
Out of 4,960 analysts
482
Total ratings
43.39%
Success rate
10.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ed Arce
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Assumes: Buy | $30 | $17.92 | +67.41% | 21 | Jun 11, 2025 | |
| MTVA MetaVia | Reiterates: Buy | $12 | $0.65 | +1,746.15% | 3 | Apr 16, 2025 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $75 | $4.20 | +1,685.71% | 27 | Apr 11, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Buy | $60 | $18.51 | +224.15% | 31 | Apr 10, 2025 | |
| AKBA Akebia Therapeutics | Reiterates: Buy | $7.5 | $3.19 | +135.11% | 36 | Apr 4, 2025 | |
| IVA Inventiva | Reiterates: Buy | $13 | $4.40 | +195.45% | 16 | Apr 2, 2025 | |
| GALT Galectin Therapeutics | Reiterates: Neutral | n/a | $4.10 | - | 17 | Apr 2, 2025 | |
| TLPH Talphera | Reiterates: Buy | $6 | $0.49 | +1,117.78% | 6 | Apr 1, 2025 | |
| ALGS Aligos Therapeutics | Reiterates: Buy | $70 | $10.20 | +586.27% | 6 | Mar 31, 2025 | |
| DRRX DURECT | Reiterates: Neutral | n/a | $1.92 | - | 13 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $26.93 | - | 8 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $240 | $4.72 | +4,990.14% | 17 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.45 | - | 24 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $32 | $7.11 | +350.07% | 11 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $35 | $66.37 | -47.27% | 22 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $75 | $49.23 | +52.35% | 25 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $29 → $21 | $9.43 | +122.69% | 22 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $72 | $71.52 | +0.67% | 30 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $400 → $405 | $414.68 | -2.33% | 17 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5.5 | $6.11 | -9.98% | 9 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $95 | $29.78 | +219.01% | 6 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $8.83 | +103.85% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $4.38 | +196.72% | 18 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $3.59 | +39.28% | 18 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $25.00 | +92.00% | 2 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $7.5 | $6.93 | +8.23% | 11 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.74 | +572.04% | 13 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $13 | $12.27 | +5.95% | 16 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $1.46 | - | 8 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $22.57 | +10.77% | 8 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.49 | - | 4 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.20 | - | 2 | Nov 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $7 | $26.00 | -73.08% | 1 | Nov 10, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $39.11 | -46.31% | 1 | Sep 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.66 | - | 2 | Feb 15, 2017 |
Travere Therapeutics
Jun 11, 2025
Assumes: Buy
Price Target: $30
Current: $17.92
Upside: +67.41%
MetaVia
Apr 16, 2025
Reiterates: Buy
Price Target: $12
Current: $0.65
Upside: +1,746.15%
Unicycive Therapeutics
Apr 11, 2025
Reiterates: Buy
Price Target: $75
Current: $4.20
Upside: +1,685.71%
Arcturus Therapeutics Holdings
Apr 10, 2025
Reiterates: Buy
Price Target: $60
Current: $18.51
Upside: +224.15%
Akebia Therapeutics
Apr 4, 2025
Reiterates: Buy
Price Target: $7.5
Current: $3.19
Upside: +135.11%
Inventiva
Apr 2, 2025
Reiterates: Buy
Price Target: $13
Current: $4.40
Upside: +195.45%
Galectin Therapeutics
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.10
Upside: -
Talphera
Apr 1, 2025
Reiterates: Buy
Price Target: $6
Current: $0.49
Upside: +1,117.78%
Aligos Therapeutics
Mar 31, 2025
Reiterates: Buy
Price Target: $70
Current: $10.20
Upside: +586.27%
DURECT
Mar 27, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.92
Upside: -
Mar 24, 2025
Reiterates: Neutral
Price Target: n/a
Current: $26.93
Upside: -
Mar 19, 2025
Reiterates: Buy
Price Target: $240
Current: $4.72
Upside: +4,990.14%
Mar 18, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.45
Upside: -
Mar 13, 2025
Reiterates: Buy
Price Target: $32
Current: $7.11
Upside: +350.07%
Mar 10, 2025
Maintains: Buy
Price Target: $24 → $35
Current: $66.37
Upside: -47.27%
Mar 3, 2025
Maintains: Buy
Price Target: $72 → $75
Current: $49.23
Upside: +52.35%
Feb 28, 2025
Reiterates: Buy
Price Target: $29 → $21
Current: $9.43
Upside: +122.69%
Feb 28, 2025
Maintains: Buy
Price Target: $66 → $72
Current: $71.52
Upside: +0.67%
Feb 27, 2025
Maintains: Buy
Price Target: $400 → $405
Current: $414.68
Upside: -2.33%
Feb 21, 2025
Reiterates: Neutral
Price Target: $5.5
Current: $6.11
Upside: -9.98%
Feb 18, 2025
Reiterates: Buy
Price Target: $95
Current: $29.78
Upside: +219.01%
Feb 11, 2025
Reiterates: Buy
Price Target: $18
Current: $8.83
Upside: +103.85%
Feb 7, 2025
Reiterates: Buy
Price Target: $13
Current: $4.38
Upside: +196.72%
Jan 21, 2025
Reiterates: Buy
Price Target: $5
Current: $3.59
Upside: +39.28%
Jan 14, 2025
Reiterates: Buy
Price Target: $48
Current: $25.00
Upside: +92.00%
Dec 4, 2024
Reiterates: Neutral
Price Target: $7.5
Current: $6.93
Upside: +8.23%
Sep 10, 2024
Reiterates: Buy
Price Target: $5
Current: $0.74
Upside: +572.04%
Sep 6, 2024
Reiterates: Buy
Price Target: $13
Current: $12.27
Upside: +5.95%
Mar 20, 2024
Upgrades: Neutral
Price Target: n/a
Current: $1.46
Upside: -
Dec 27, 2023
Reiterates: Buy
Price Target: $25
Current: $22.57
Upside: +10.77%
May 3, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.49
Upside: -
Nov 18, 2020
Downgrades: Neutral
Price Target: n/a
Current: $26.20
Upside: -
Nov 10, 2017
Assumes: Buy
Price Target: $7
Current: $26.00
Upside: -73.08%
Sep 11, 2017
Initiates: Buy
Price Target: $21
Current: $39.11
Upside: -46.31%
Feb 15, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.66
Upside: -